[ 20 ], and the C-peptide-positive patients who were randomly allocated to receive sitagliptin had a nonsignificant trend toward decreased HbA1c levels, mean glucose levels, and duration of hyperglycemia.
← all excerpts
DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
1
—
—